Celldex Therapeutics, Inc. today announced that Michael Yellin, MD, Vice President of Clinical Science, will present final results from a Phase 1 trial of CDX-301 in healthy volunteers in an oral presentation at the American Society for Blood and Marrow Transplantation 2013 BMT Tandem Meetings.
http://www.globenewswire.com/news-release/2013/02/11/522508/10021341/en/Celldex-Announces-Upcoming-Oral-Presentation-on-CDX-301-at-the-American-Society-for-Blood-and-Marrow-Transplantation-2013-BMT-Tandem-Meetings.html
http://www.globenewswire.com/news-release/2013/02/11/522508/10021341/en/Celldex-Announces-Upcoming-Oral-Presentation-on-CDX-301-at-the-American-Society-for-Blood-and-Marrow-Transplantation-2013-BMT-Tandem-Meetings.html
No comments:
Post a Comment